title: HER2-directed T-cell receptor-mimicking antibody: a "Me Too" or an example of novel antitumor aggressive mimicry?
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Bianchini
authors.forename: Luca
authors.initials: L
authors.lastname: Gianni
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D005260:Female; D015789:HLA-A2 Antigen / Q000187:drug effects*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000187:drug effects*; D009369:Neoplasms / Q000188:drug therapy*; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011948:Receptors, Antigen, T-Cell / Q000819:agonists*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D015789:HLA-A2 Antigen; D047908:Intracellular Signaling Peptides and Proteins; D015514:Oncogene Proteins, Fusion; D018719:Erb-b2 Receptor Tyrosine Kinases; D011948:Receptors, Antigen, T-Cell; D000068878:Trastuzumab; C508053:ERBB2 protein, human